The EPS projection of Seattle Genetics, Inc. (NASDAQ:SGEN) for quarter ended 2016-09-30 is $-0.32. A week before, the EPS forecast was $-0.32 against target of $-0.32, a month earlier. This estimate stood at $-0.32 60 days earlier versus forecast of $-0.32 90 days earlier, confirming a deviation of 0%.
Seattle Genetics, Inc. (NASDAQ:SGEN) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 3.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Seattle Genetics, Inc. (NASDAQ:SGEN) in the preceding 120, 60, 30 and 90 days were 6, 6, 0 and 6, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Seattle Genetics, Inc. (NASDAQ:SGEN) was $-0.32. This projection was computed after accounting 9 calls. As reported on 2016-04-28 the EPS was $-0.15. The change was $-0.04, demonstrating a percentage deviation of -36.36%. The projections confirmed a standard deviation of 0.05.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Seattle Genetics, Inc. (NASDAQ:SGEN) stands at $109.432 and the median estimate at $107.85. Almost 5 analysts announced their estimates.
The highest estimate is $117.563 while the lowest target is $104.7 showing standard deviation of 5.074%.
As many as 5 analysts released sales estimates reised in upside while 5 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 5 revised sales number projection on upside while 5 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 5 hiked sales estimations and 5 reduced sales forecast. Seattle Genetics, Inc. (NASDAQ:SGEN) stated that the change in forecast was 1.891%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...